Recommendations for Interpreting and Reporting Silent Carrier and Disease-Modifying Variants in SMA Testing Workflows
Genetic testing for SMA diagnosis, newborn screening, and carrier screening has become a significant public health interest worldwide, driven largely by the development of novel and effective molecular therapies for the treatment of spinal muscular atrophy (SMA) and the corresponding updates to test...
Main Authors: | John N. Milligan, Laura Blasco-Pérez, Mar Costa-Roger, Marta Codina-Solà, Eduardo F. Tizzano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/13/9/1657 |
Similar Items
-
Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
by: Andrés López-Cortés, et al.
Published: (2022-06-01) -
Evaluation of Mean Percentage of Full-Length SMN Transcripts as a Molecular Biomarker of Spinal Muscular Atrophy
by: Marianna Maretina, et al.
Published: (2022-10-01) -
Massachusetts’ Findings from Statewide Newborn Screening for Spinal Muscular Atrophy
by: Jaime E. Hale, et al.
Published: (2021-05-01) -
The importance of SMA screening tests in newborns – review
by: Barbara Rusinowska
Published: (2022-07-01) -
SMA carrier testing using Real-time PCR as a potential preconception screening tool
by: Noura Raafat Eissa, et al.
Published: (2022-02-01)